10 November 2022 in Journal of Clinical Oncology
PURPOSE: There are significant disparities in care and outcomes for patients with leukemias and multiple myeloma (MM). To evaluate the extent to which clinical trials (CTs) match the demographic and geographic diversity of populations affected by leukemias and MM. METHODS: CTs leading to drug approval were identified from the US Food and Drug Administration databases. Demographic and geographic data were collected from ClinicalTrials.gov and primary manuscripts. Standard descriptive statistics were used to summarize the data in frequencies and proportions, including 95% CIs, by race, ethnicity, sex, and malignancy subtypes. RESULTS: A total of 41 (67.2%) trials leading to drug approval reported data on race and 20 (48.8%) on ethnicity. These trials included 13,731 patients, of whom 11,209 (81.6%) were White. Among minorities, Asian-Pacific Islanders and Blacks had the highest representation in chronic myeloid leukemia, 147 (12.7%) and 61 (5.3%), and lowest in chronic lymphocytic leukemia, 55 (3%) and 20 (1.1%), respectively. Proportions for Blacks, Native Americans, and Hispanics were significantly low, reflecting under-representation in trials compared with the proportion in the general population. Females were also under-represented in acute myeloid leukemia (44.7% v 60.5%, P < .0001), and males in MM (55.3% v 60.2%, P < .0001) and chronic myeloid leukemia (55.2% v 62.9%, P < .0001). The geographic distribution of trials showed inadequate regional and state participation compared with mortality for all malignancies except MM. CONCLUSION: There are significant demographic and geographic under-representation and imbalances in pivotal CTs leading to drug approvals for leukemias and MM compared with the population affected. These disparities need to be addressed to make results applicable to all relevant populations.
19 March 2023 in Trauma, Violence, & Abuse
The COVID-19 pandemic has fostered an environment for increased risk of child maltreatment (CM) as families experience increased psychosocial and financial burdens and spend unprecedented amounts of time together in the home. This narrative review aimed to summarize empirical findings on existing or new pandemic-related risk factors among caregivers. A combination of search terms related to CM and COVID-19 were used to identify articles published within five databases between February 2020 and July 2022. Literature searches produced 113 articles, of which 26 published across 12 countries met inclusion criteria. Four previously well-established risk factors for CM perpetration continued to persist during the pandemic, including stress, parental mental health, financial concerns, and parental substance use. Of note, inconsistent definitions and measures were used to capture these risk factors. Several additional emerging and understudied risk factors were also identified among limited articles, such as food insecurity and parental education. Findings emphasize the ongoing need for evidence-based interventions to address CM risk during the pandemic, including parent training programs. However, consolidated measures and consistent conceptualization of risk factors are needed to advance the study of CM. Going forward, practitioners and researchers should (a) strengthen the identification process for families at greatest risk for CM, and particularly those vulnerable to pandemic-related stressors; and (b) augment delivery of CM prevention strategies and evidence-based programs to fit the pandemic context.
8 October 2025 in Journal of Family Violence
18 May 2023 in The Journal of Pharmacology and Experimental Therapeutics
ID 23576 Poster Board 209 A key goal in preclinical pain research is improvement of the translational value of findings by modeling pain states elicited in humans. Examining the expression and treatment of pain-related disruption of behavior represents one approach to improving the alignment between preclinical pain research and clinical settings. Past studies support the ability of the opioid, analgesic morphine to restore pain-related depression of behavior in mice and rats. The goal of the present study was to examine the role of mu opioid receptor agonist efficacy in the treatment of pain-related depression of behavior. The partial mu opioid receptor agonist buprenorphine, and the full mu opioid receptor agonist methadone were examined for their ability to block lactic-acid induced depression of Nestlet shredding in male and female ICR mice. At the start of test sessions, a 5 × 5 cm Nestlet was weighed and suspended from the wire lid of the home cage. Under control conditions, mice removed pieces of the suspended Nestlet to build nests. Intraperitoneal injection of 0.18% lactic acid disrupted Nestlet shredding. Unlike morphine, buprenorphine failed to restore acid-induced depression of shredding. In contrast, methadone significantly blocked acid-induced depression of shredding. In the absence of acid, both buprenorphine and methadone significantly depressed shredding. These findings suggest that opioid effects on nestlet shredding in the presence and absence of pain stimuli require different levels of MOR efficacy. Disruption of shredding in the absence of a pain stimulus has lower efficacy requirements than treatment of pain-related depression of behavior. Support/Funding Information: NIA Grant R15AG055041